A closed-loop insulin delivery system, also referred to as an artificial pancreas, was found to be more effective than sensor-augmented insulin pump therapy in patients with type 1 diabetes.
The FDA has expanded the indication for Fiasp (insulin aspart injection; Novo Nordisk) 100 Units/mL to include use in insulin infusion pumps to improve glycemic control in adults with type 1 or type 2 diabetes.
There were no clear benefits of using faster insulin aspart in closed-loop insulin therapy and the closed-loop algorithm was better adjusted to the use of standard insulin aspart.
Medical devices that can connect to the internet might be at risk for hacking, the U.S. Food and Drug Administration warned Tuesday.
Colophonium, a fast-acting adhesive and known sensitizing allergen, may cause dermatologic reactions in children using devices to manage diabetes.
Highest rates reported among preschoolers, children, and adolescents aged younger than 15 years
Real-world usage of an implantable continuous glucose monitoring system shows promise for improved glycemic control, sensor accuracy, and safety.
The FDA has granted 510(k) market clearance to the OneDraw A1C Test system, which monitors HbA1c levels in individuals with diabetes for long-term glucose control.
A review published in the Annals of Internal Medicine outlines the 2019 ADA guidelines for self-monitoring of blood glucose and the use of continuous glucose monitors and automated insulin delivery systems.
Years before the first closed-loop insulin delivery system was approved, patients with diabetes had already been implementing the technology into their own care.
Few smartphone apps for self-management of type 2 diabetes provide sufficient real-time action prompts or education on blood glucose monitoring.